Company profile for Marinus Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Marinus Pharmaceuticals, Inc. is committed to improving the lives of patients suffering from drug-resistant seizures and neuropsychiatric disorders through the development of a new and safe drug candidate, ganaxolone, which offers an alternative treatment option for acute and chronic illnesses. Ganaxolone is a drug candidate designed to exhibit antiepileptic, anxiolytic, antidepressant, and sedative activity by virtue of its G...
Marinus Pharmaceuticals, Inc. is committed to improving the lives of patients suffering from drug-resistant seizures and neuropsychiatric disorders through the development of a new and safe drug candidate, ganaxolone, which offers an alternative treatment option for acute and chronic illnesses. Ganaxolone is a drug candidate designed to exhibit antiepileptic, anxiolytic, antidepressant, and sedative activity by virtue of its GABAA receptor modulating properties.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
170 N. Radnor Chester Road, Suite 250 Radnor, PA 19087-5279
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.orion.fi/en/newsroom/all-news/releases/press-releases/2024/orion-and-marinus-terminate-agreement-for-ganaxolone-in-europe/

PRESS RELEASE
02 Jan 2025

https://www.orion.fi/en/newsroom/all-news/releases/press-releases/2024/orion-and-marinus-terminate-agreement-for-ganaxolone-in-europe/

#N/A
30 Dec 2024

https://www.businesswire.com/news/home/20241230307666/en

BUSINESSWIRE
30 Dec 2024

https://www.fiercepharma.com/pharma/marinus-lops-45-staff-seizure-med-ztalmy-remains-limbo-following-phase-3-misses

FIERCE PHARMA
13 Nov 2024

https://www.businesswire.com/news/home/20241112598483/en

BUSINESSWIRE
12 Nov 2024

https://www.businesswire.com/news/home/20241024735870/en

BUSINESSWIRE
24 Oct 2024

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty